U.S. markets closed

Athenex (ATNX) in Focus: Stock Moves 6.5% Higher

Zacks Equity Research

Athenex, Inc. ATNX was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 26.1% in the past one-month time frame.

The company has seen no estimate revisions over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Athenex currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.  

Athenex, Inc. Price

Athenex, Inc. Price

Athenex, Inc. price | Athenex, Inc. Quote

A better-ranked stock in the Medical - Biomedical and Genetics industry is Adaptimmune Therapeutics PLC ADAP, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ATNX going up? Or down? Predict to see what others think: Up or Down

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report
 
Athenex, Inc. (ATNX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research